At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 109 enrolled
Drug / intervention
BMS-986322 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis
In Brief
A Phase 2 clinical trial evaluating BMS-986322 and Placebo for Psoriasis. Completed, enrolled 109 participants across 35 sites in 5 countries.
Detailed Summary
The purpose of this study is to evaluate clinical effectiveness and safety of BMS-986322 in participants with moderate-to-severe psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesAustralia, Canada, Japan, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202420252026
First PostedFeb 2023
Enrollment StartApr 2023
Primary CompletionAug 2024
TodayJul 2026
First PostedFeb 16, 2023
Enrollment StartApr 3, 2023
Primary CompletionAug 6, 2024
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 3.4 years ago
Interventions
BMS-986322drug
Specified dose on specified days
Placeboother
Specified dose on specified days